HIGHLIGHTS
- who: Henry D. Reyes et al. from the University of California Department of Obstetrics and Gynecology, The Holden Comprehensive Cancer Center, University of Iowa, Iowa City, IA, USA have published the paper: High stathmin expression is a marker for poor clinical outcome in endometrial cancer: An NRG oncology group/gynecologic oncology group study, in the Journal: (JOURNAL)
- what: From this trial showed that patients treated with the three-drug regimen TAP had a better overall response rate (57% vs 34%), median progression-free survival (PFS) (8.3 vs. 5.3 months), and median overall survival . . .
If you want to have access to all the content you need to log in!
Thanks :)
If you don't have an account, you can create one here.